Skip to main content
Erschienen in: Reproductive Biology and Endocrinology 1/2021

Open Access 01.12.2021 | Research

Evaluation of vitamin D receptor expression in uterine leiomyoma and nonneoplastic myometrial tissue: a cross‐sectional controlled study

verfasst von: Maria Simone Oliveira Lima, Benedito Borges da Silva, Menandro Lima de Medeiros, Alesse Ribeiro dos Santos, Emerson Davi do Nascimento Brazil, Walberto Monteiro Neiva Eulálio Filho, Jerusia Oliveira Ibiapina, Antônio Gilberto Albuquerque Brito, Pedro Vitor Lopes Costa

Erschienen in: Reproductive Biology and Endocrinology | Ausgabe 1/2021

Abstract

Background

Uterine myomas are the most frequent benign solid pelvic tumors in women of reproductive age. At present, uterine myomas are the most common indication for hysterectomy because of the morbidity they cause, including intense bleeding, compression of adjacent organs, pain, and infertility. Some studies show that vitamin D receptor (VDR) expression is correlated with the etiology of uterine leiomyomas. This study aimed to assess the expression of VDR in uterine leiomyoma and nonneoplastic myometrial tissue.

Methods

A controlled cross-sectional study involving 40 women who underwent abdominal hysterectomy the Department of Gynecology of the Getúlio Vargas Hospital of Federal University of Piauí, Brazil, was performed to compare the immunohistochemical expression of VDR in samples of uterine leiomyoma tissue with adjacent nonneoplastic myometrial tissue. The mean percetages of stained nuclei in the two groups was compared by Student’s t teste, with significance established at p < 0.05.

Results

The percentage of cells with nuclei stained by anti-VDR in the myometrial and leiomyoma tissue was 79.52 % (± 4.32) and 60.22 % (± 7.24), respectively (p < 0.0001).

Conclusions

The mean percentage of nuclei expressing VDR was significantly lower in the uterine leiomyoma than in nonneoplastic myometrial tissue.
Hinweise

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
BSA
Bovine Serum Albumin
ECM
Extracellular Matrix
VDR
Vitamin D Receptor

Introduction

Uterine leiomyomas are the most frequent benign solid pelvic tumors in women of reproductive age [1]. They are usually detected between 30 and 40 years of age [2]. Furthermore, they may be related to biological changes in growth and development and are generally influenced by sex hormones, primarily estrogen [3]. Leiomyomas can have a significant impact on women’s quality of life. Depending on their anatomical position, quantity, and size, they can cause symptoms such as heavy bleeding, pain, compression of adjacent organs, and infertility [4]. They may also cause adverse gestational outcomes, such as miscarriages, fetal anomalies, and an increase in the indication for cesarean Secs. [5, 6].
Uterine leiomyomas are characterized by excessive extracellular matrix (ECM) deposition as well as an increase in cell proliferation [7]. Changes in this process of degradation and remodeling may contribute to the genesis of leiomyomas. The etiology of leiomyomas has not yet been fully clarified, and recently, it has been suggested that vitamin D can play an important role in their development [8]. The active metabolite of vitamin D, recognized as a steroid hormone, has been shown to be an inhibitor of cell proliferation and extracellular matrix production in fibroid tissue, thus reducing the volume of leiomyomas [9, 10].
Vitamin D exerts its effects by activating its cell receptor, vitamin D receptor (VDR), which consequently changes the transcription rates of the target genes responsible for various biological responses [10]. Such effects include immunomodulatory, antiproliferative, differentiating, and antineoplastic activities that may lead to actions such as the inhibition of cell proliferation, the induction of differentiation, and the induction of apoptosis. Furthermore, it can lead to protection from the malignant transformation of cells as well as the inhibition of cell growth [1113].
Recent studies have evaluated the expression of VDR in both the myometrium and endometrium of the human uterus. Feng et al. [14] conducted a study to determine the expression of VDR in uterine leiomyoma tissue. Samples of myoma and myometrial tissue from different sites in five women who underwent hysterectomy were evaluated, and high VDR expression was observed in the central part of the leiomyoma samples compared to the myometrial samples. The expression of VDR in the leiomyoma margin did not differ from that in the central region of the lesion or the adjacent myometrium, but different levels of VDR expression were found depending on the location of the lesion, and a biological role of vitamin D signaling in the pathology leiomyoma was suggested. Another more recent study conducted by Al-Hendy et al. [15] evaluated the role of 1.25 (OH) 2D3 in the expression of sex steroid receptors in uterine fibroid cells in 14 patients, where they identified that the expression of VDR was lower in the fibroid tissue in 60 % of the cases (8) than in the adjacent myometrium.
Evidence shows that the expression of VDR in most cells could be an important cellular biomarker associated with the etiology of uterine leiomyomas [16]. However, there have been few studies evaluating the expression of this biomarker in uterine leiomyomatosis. Thus, the present study aimed to evaluate VDR expression in uterine leiomyomas and in adjacent nonneoplastic myometrial tissue.

Patients and methods

This was a controlled cross-sectional study involving 40 Brazilian women who attended the Gynecological Department of the Getúlio Vargas Hospital of Federal University of Piauí, Brazil, from April to December 2017. The woman included in this study were of reproductive age (30 to 45 years; mean age 40.7 years), had symptomatic uterine leiomyomatosis and had undergone abdominal hysterectomy surgery. The exclusion criteria for the study were a postmenopausal status, hepatic, metabolic, cardiovascular, and renal diseases, reports of other types of malignancy, and previous hormonal or surgical treatment for leiomyoma. In addition, the following data were collected from medical records: age, parity, ethnicity, body mass index (BMI), fibroid size and uterine volume.
Regarding parity, 35 patients had had children and 5 had had no pregnancies. Regarding ethnicity, 27 patients were Afro-Brazilian and 13 were white. The mean body mass index was 26.26 (21.3–32.9). In particular, 17 (42.5 %) patients had a normal weight (19–24.9), 17 (42.5 %) were overweight (25–29.9), and 6 (15 %) were obese. The mean myoma size was 7.61 cm, ranging from 1.3 to 83.1 cm. The mean uterine volume was 370.2 cm3, ranging from 76.8 to 1438.0 cm3 (Table 1).
Table 1
Patient’s characteristics
 
N
%
Age
 30–39
14
35
 40–45
26
65
Parity
 Yes
35
87.5
 No
5
12.5
Ethinicity
 White
13
33
 Afro-Brazilian
27
67
Body Mass Index
 Eutrophic
17
42.5
 Pre-obese
17
42.5
 Obese
6
15
Myoma size (cm)
 Less than 5
22
55
 5–10
15
37
 More than 10
3
8
Uterine Volume (cm3)
 Less than 160
6
15
 161–500
28
70
 More than 500
6
15
Tissue samples of uterine leiomyomas and nonneoplastic myometrial tissue of approximately 1 cm in diameter were collected. Nonneoplastic tissue samples were collected from uterine regions clear of fibroids and at least 5 cm away from any myoma at the time of the abdominal hysterectomy procedure. Tissue samples were fixed in a 10 % buffered formalin solution for a period of 12–24 h. Then, all histological procedure steps were performed and the samples were embedded in paraffin. These samples were cut into 3 μm-thick sections. Some of the sections were stained with hematoxylin and eosin to confirm the diagnosis of uterine leiomyomatosis and identification of normal myometrial tissue, while other samples were reserved for immunohistochemical analysis.
In the immunohistochemical analysis, a rabbit anti-vitamin D3 receptor polyclonal antibody (orb214726, Biorbyt, UK), was used to stain for VDR at a dilution of 1:25 with bovine serum albumin (BSA). These sections were deparaffinized in xylol for 5 min, dehydrated in absolute ethanol and washed in buffered saline solution at pH 7.4 for 5 min. Then, the sections were treated for 5 min with 3 % hydrogen peroxide (H2O2) diluted in buffered solution to block the endogenous peroxide. For antigen recover, the slides were placed in racks containing 0.21 % citric acid (pH 6.0) and heated in a microwave oven for 15 min at maximum power. Phosphate-buffered saline containing Tween (PBS-Tween) was added to the slides after they had been cooled for 20 min. The tissue samples were incubated with specific primary antibody overnight at 4ºC, then the slides were subjected to three washes in PBS, dried and incubated with “In Vision TM System (DAKO, Code K 1672)” for 1 h at 37º C. Once again, the slides were washed in running water, distilled water and stained with Mayer’s hematoxylins for 30 s. The cuts were embedded with 100 % alcohol and xylol for dehydration and then placed in coverslips and Entellan resin. Finally, the slides were examined by light microscopy. Formalin-fixed and paraffin-embedded human lung cancer tissue stained with VDR antibody (dilution at 1:200) was used for positive control.
Quantitative biomarker expression was evaluated by two observers who were blinded to the sample types. These observers quantitatively counted the cells with positively stained nuclei (under 400× magnification) using an optical microscope connected to a video camera. For the quantification of VDR expression, a minimum of 500 cells were counted in each slide, whether stained with the anti – VDR antibody or not, at a magnification of 400 X beginning with the area in which VDR expression was greatest. In each case, the percentage of stained cells was obtained as the ratio of the number of cells with stained nuclei to number of cells multiplied by 100.
The results in the two groups were analyzed as the mean and standard error using Student’s t-test, and the average percentages of cells stained in the myoma and myometrial tissue were analyzed descriptively using boxplots. To verify the normality of the data, the Shapiro-Wilk test was performed. The correlation of the percentage of cells stained in the fibroid with the tumor size and uterine volume was examined with the Spearman coefficient. P < 0.05 was considered statistically significant. The Internal Review Board of the Federal University of Piauí approved the study, and all patients signed the free informed consent form prior to the study.

Results

Under light microscopy, we observed a scarcity of brown nuclei stained by anti-VDR antibody in the fibroma samples and many nuclei stained in the adjacent normal myometrial samples (Fig. 1). The mean percentage and standard deviation of VDR expression was 79.52 ± 4.32 in the myometrial tissue and 60.22 ± 7.24 (p < 0.0001) in the leiomyoma tissue, as described in Table 2 and represented in Fig. 2. There was no statistical correlation of expression of vitamin D receptor expression in uterine leiomyoma tissue with age, parity, tumor size, uterine volume or nutritional status (Table 3).
Table 2
Mean percentage of nuclei stained by anti-vitamin D receptor antibody in myoma and in nonneoplastic myometrial tissue
Group
N
Mean
Standard error
Median
Minimum
Maximum
p-value*
Control
 (1)
40
79.52
4.32
79.91
70.00
89.00
0.0001
Study
 (2)
40
60.22
7.24
58.55
50.00
75.00
 
Source: The Author
1-Myometrium; 2-Myoma
*p-value of the t-test for equality of means
Table 3
Correlation between vitamin D receptor expression in uterine leiomyomas and clinical variables
Variables
correlation coeficiente (r)a
p
Age
0.116
0.477
Parity
0.093
0.567
Tumor size
0.129
0.428
Uterine volume
-0.067
0.682
Nutricional status
-0. 078
0.634
acorrelation coeficiente of Spearman

Discussion

In this study, we evaluated the expression of the biomarker VDR in human uterine leiomyoma tissue and compared it that in nonneoplastic myometrial tissue. Studies demonstrating the identification of VDR expression in most cells and the ability of some cells to produce active forms of vitamin D have suggesting an influence of this vitamin on the pathogenesis of uterine fibroids [8, 9, 17, 18].
The results of the present study demonstrate reduced VDR expression in leiomyoma tissue compared with myometrial tissue,suggesting an association with the pathogenesis and development of human uterine leiomyomatosis. The cause of the reduction in the expression of these receptors is still unknown, and it is not clear whether it occurs as an event related to the initiation or progression of uterine leiomyomas. A study by Halder et al. [8] corroborates our results. They evaluated the risk of benign uterine tumors associated with reduced levels of VDR protein in 40 patients and determined the biological function of 1.25 (OH) 2D3 in the regulation of proteins associated with the extracellular matrix, which are fundamental in the formation of leiomyomas, and found reduced VDR levels in more than 60 % of the uterine tumors analyzed compared with the adjacent myometrium. In their study, the levels of VDR in the uterine myoma samples were significantly lower than the levels in the adjacent myometrial samples, similar to the results of the present study.
Increased proliferation and Wnt/β-catenin pathway deregulation play a role in the development and growth of leiomyomas. Vitamin D exerts an antiproliferative effect on HULP cells through cell growth arrest and Wnt/β-catenin pathway inhibition [19]. The reduction in VDR expression would be a factor reducing the antiproliferative activity of vitamin D, thereby contributing to the pathogenesis of uterine leiomyomas.
A large cross-sectional study was conducted involving 21,746 women between 15 and 49 years of age from seven countries, Brazil, Canada, France, Germany, Italy, South Korea, and the United Kingdom, and women who were between 18 and 49 years of age from the United States. The authors found a prevalence of myomas of 7 % among Brazilian women [20]. According to the literature, the incidence of myomas is 2–3 times higher in black populations and are more often symptomatic, larger, and multiple in nature [21]. In the present study, all the evaluated women were of reproductive age; therefore, they had high hormone levels. Additionally, 67 % were Afro-descendants, thus presenting favorable characteristics for the etiology of the these uterine tumors.
In the etiology of myomas, in addition to the genetic, growth, and hormonal factors involved, other factors include age, family history, obesity, arterial hypertension, nulliparity, and diet (red meats, alcohol, caffeine, etc.) [22]. Obesity is associated with the increased secretion of adipokines, which significantly influence the growth and proliferation of tumor stroma and malignant cells [23]. In our study, 57.5 % of the women were overweight, and five of them were nulliparous.
Al-Hendy et al. [15], who researched the role of 1.25 (OH) 2D3 in the expression of sex steroid receptors in leiomyoma cells, realized that the deregulation of steroid hormones and their receptors could be a primary factor of myoma growth since 1.25 (OH) 2D3 VDR expression but acts as an antiestrogenic agent in these cells. Moreover, they showed a significant decrease in estrogenic receptor levels in leiomyoma cells treated with 1.25 (OH) 2D3 and analyzed for receptor expression and location (p < 0.05). In contrast, 1.25 (OH) 2D3 induced the expression of its own VDR, suggesting that 1.25 (OH) 2D3 acts as an antagonist of hormone receptors with antiestrogenic and antiprogesteronic functions.
Furthermore, Halder et al. [9] studied this antiestrogenic influence of vitamin D when they examined the effect of 1,25-dihydroxyvitamin D3 on fibrosis-related protein expression in TGF-3 induced uterine leiomyoma cells in vitro. Myoma cells were treated with TGF-3 with or without vitamin D. They identified that TGF-3 induced the expression of fibronectin and collagen protein type 1 in myoma cells, and this effect was suppressed by vitamin D, which was considered an antifibrotic factor in the treatment of benign uterine myomas.
Paffoni et al. [18] studied the serum levels of vitamin D in women with myoma and revealed that the vitamin D concentration was significantly lower in women with myomas than in women in the control group (11.1 and 18.0 ng/ml, respectively; p < 0.010 and OR = 2.2). Similar results were obtained by Baird et al. (2013), who evaluated vitamin D and the risk of uterine myomas and found that women with sufficient vitamin D had an estimated 32 % reduction in the incidence of myomas compared to those with insufficient vitamin D.
In addition, Sabry et al. [24] investigated whether low serum levels of vitamin D are correlated with increases in the risk and occurrence of uterine myomas and found that reduced serum levels of 25-(OH) vitamin D were significantly associated with the occurrence of myomas. A statistically significant inverse correlation was also observed between the serum levels of 25-(OH) vitamin D and the total leiomyoma volume within the case cohort.
The above studies indicate that the loss of vitamin D functions due to the reduction of vitamin D3 levels and/or reduced expression of VDR may be associated with the growth and development of several types of neoplastic lesions. Our results reinforce the hypothesis that low VDR expression may be associated with the growth and development of myomas, presenting itself as an important biomarker in this pathology. However, further studies are needed to assess the real importance of VDR expression in the etiopathogenesis of uterine leiomyomas.

Conclusions

In conclusion, we observed significantly reduced VDR expression in human uterine leiomyomas compared with in nonneoplastic myometrial samples.

Acknowledgements

None.

Declarations

The study was referred to the Research Ethics Committee (CEP) of the Federal University of Piaui, and all patients signed the free informed consent form prior to the study.
Not applicable.

Competing interests

None.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
1.
Zurück zum Zitat Wallach EE, Vlahos NF. Uterine myomas: an overview of development, clinical features, and management. Obstet Gynecol. 2005;105:217.CrossRef Wallach EE, Vlahos NF. Uterine myomas: an overview of development, clinical features, and management. Obstet Gynecol. 2005;105:217.CrossRef
2.
Zurück zum Zitat Barjon K, Mikhail LN. Uterine Leiomyomata (Fibroids). In: StatPearls. Treasure Island: StatPearls Publishing; 2020. Barjon K, Mikhail LN. Uterine Leiomyomata (Fibroids). In: StatPearls. Treasure Island: StatPearls Publishing; 2020.
4.
Zurück zum Zitat Giuliani E, As-Sanie S, Marsh EE. Epidemiology and management of uterine fibroids. Int J Gynaecol Obstet. 2020;149:3–9.CrossRef Giuliani E, As-Sanie S, Marsh EE. Epidemiology and management of uterine fibroids. Int J Gynaecol Obstet. 2020;149:3–9.CrossRef
5.
Zurück zum Zitat Baranov VS, Osinovskaya NS, Yarmolinskaya MI. Pathogenomics of Uterine Fibroids Development. Int J Mol Sci. 2019;20:6151.CrossRef Baranov VS, Osinovskaya NS, Yarmolinskaya MI. Pathogenomics of Uterine Fibroids Development. Int J Mol Sci. 2019;20:6151.CrossRef
6.
Zurück zum Zitat Donnez J, Arriagada P, Donnez O, Dolmans MM. Emerging treatment options for uterine fibroids. Expert Opin Emerg Drugs. 2018;23:17–23.CrossRef Donnez J, Arriagada P, Donnez O, Dolmans MM. Emerging treatment options for uterine fibroids. Expert Opin Emerg Drugs. 2018;23:17–23.CrossRef
7.
Zurück zum Zitat Baird DD, Hill MC, Schectman JM, Hollis BW. Vitamin d and the risk of uterine fibroids. Epidemiology. 2013;24:447–53.CrossRef Baird DD, Hill MC, Schectman JM, Hollis BW. Vitamin d and the risk of uterine fibroids. Epidemiology. 2013;24:447–53.CrossRef
8.
Zurück zum Zitat Halder SK, Osteen KG, Al-Hendy A. 1, 25-Dihydroxyvitamin D3 reduces extracellular matrix-associated protein expression in human uterine fibroid cells. Biol Reprod. 2013;89:150.CrossRef Halder SK, Osteen KG, Al-Hendy A. 1, 25-Dihydroxyvitamin D3 reduces extracellular matrix-associated protein expression in human uterine fibroid cells. Biol Reprod. 2013;89:150.CrossRef
9.
Zurück zum Zitat Halder SK, Goodwin JS, Al-Hendy A. 1, 25-Dihydroxyvitamin D3 reduces TGF-beta3-induced fibrosis-related gene expression in human uterine leiomyoma cells. J Clin Endocrinol Metab. 2011;96:E754-62.CrossRef Halder SK, Goodwin JS, Al-Hendy A. 1, 25-Dihydroxyvitamin D3 reduces TGF-beta3-induced fibrosis-related gene expression in human uterine leiomyoma cells. J Clin Endocrinol Metab. 2011;96:E754-62.CrossRef
10.
Zurück zum Zitat Zhang X, Nicosia SV, Bai W. Vitamin D receptor is a novel drug target for ovarian cancer treatment. Curr Cancer Drug Targets. 2006;6:229–44.CrossRef Zhang X, Nicosia SV, Bai W. Vitamin D receptor is a novel drug target for ovarian cancer treatment. Curr Cancer Drug Targets. 2006;6:229–44.CrossRef
11.
Zurück zum Zitat Nagpal S, Na S, Rathnachalam R. VDR Noncalcemic Actions of Vitamin D Receptor Ligands. Endocr Rev. 2005;26:662–87.CrossRef Nagpal S, Na S, Rathnachalam R. VDR Noncalcemic Actions of Vitamin D Receptor Ligands. Endocr Rev. 2005;26:662–87.CrossRef
12.
Zurück zum Zitat Kochupillai N. The physiology of vitamin D: Current concepts. Indian J Med Res. 2008;127:256–62.PubMed Kochupillai N. The physiology of vitamin D: Current concepts. Indian J Med Res. 2008;127:256–62.PubMed
13.
Zurück zum Zitat Brakta S, Diamond JS, Al-Hendy A, Diamond MP, Halder SK. Role of vitamin D in uterine fibroid biology. Fertil Steril. 2015;104:698–706.CrossRef Brakta S, Diamond JS, Al-Hendy A, Diamond MP, Halder SK. Role of vitamin D in uterine fibroid biology. Fertil Steril. 2015;104:698–706.CrossRef
14.
Zurück zum Zitat Feng L, Jayes FL, Jung SH, Leppert PC. Vitamin D receptor (VDR) is over- expressed in the center of uterine fibroids. Fertil Steril. 2010;94:75.CrossRef Feng L, Jayes FL, Jung SH, Leppert PC. Vitamin D receptor (VDR) is over- expressed in the center of uterine fibroids. Fertil Steril. 2010;94:75.CrossRef
15.
Zurück zum Zitat Al-Hendy A, Diamon MP, El-Sohemy A, Halder SK. 1,25-Dihydroxyvitamin D3 Regulates Expression of Sex Steroid Receptors in Human Uterine Fibroid Cells. J Clin Endocrinol Metab. 2015;100:E572-82.CrossRef Al-Hendy A, Diamon MP, El-Sohemy A, Halder SK. 1,25-Dihydroxyvitamin D3 Regulates Expression of Sex Steroid Receptors in Human Uterine Fibroid Cells. J Clin Endocrinol Metab. 2015;100:E572-82.CrossRef
16.
Zurück zum Zitat Halder SK, Goodwin JS, Al-Hendy A. Vitamin D exhibits antiestrogenic effects in human uterine leiomyoma cells. Fertil Steril. 2010;94:219-20. Halder SK, Goodwin JS, Al-Hendy A. Vitamin D exhibits antiestrogenic effects in human uterine leiomyoma cells. Fertil Steril. 2010;94:219-20.
17.
Zurück zum Zitat Mohammadi R, Tabrizi R, Hessami K, Ashari H, Nowrouzi-Sohrabi P, Hosseini-Bensenjan M, et al. Correlation of low serum vitamin-D with uterine leiomyoma: a systematic review and meta-analysis. Reprod Biol Endocrinol. 2020;18:85.CrossRef Mohammadi R, Tabrizi R, Hessami K, Ashari H, Nowrouzi-Sohrabi P, Hosseini-Bensenjan M, et al. Correlation of low serum vitamin-D with uterine leiomyoma: a systematic review and meta-analysis. Reprod Biol Endocrinol. 2020;18:85.CrossRef
18.
Zurück zum Zitat Paffoni A, Somigliana E, Vigano P, Benaglia L, Cardellicchio L, Pagliardini L, et al. Vitamin D status in women with uterine leiomyomas. J Clin Endocrinol Metab. 2013;98:E1374-8.CrossRef Paffoni A, Somigliana E, Vigano P, Benaglia L, Cardellicchio L, Pagliardini L, et al. Vitamin D status in women with uterine leiomyomas. J Clin Endocrinol Metab. 2013;98:E1374-8.CrossRef
19.
Zurück zum Zitat Corachán A, Ferrero H, Aguilar A, Garcia N, Monleon J, Faus A, Cervelló I, Pellicer A. Inhibition of tumor cell proliferation in human uterine leiomyomas by vitamin D via Wnt/β-catenin pathway. Fertil Steril. 2019;111(2):397–407.CrossRef Corachán A, Ferrero H, Aguilar A, Garcia N, Monleon J, Faus A, Cervelló I, Pellicer A. Inhibition of tumor cell proliferation in human uterine leiomyomas by vitamin D via Wnt/β-catenin pathway. Fertil Steril. 2019;111(2):397–407.CrossRef
20.
Zurück zum Zitat Zimmermann A, Bernuit D, Gerlinger C, Schaefers M, Geppert K. Prevalence, symptoms and management of uterine fibroids: an international internet-based survey of 21,746 women. BMC Womens Health. 2012;12:6.CrossRef Zimmermann A, Bernuit D, Gerlinger C, Schaefers M, Geppert K. Prevalence, symptoms and management of uterine fibroids: an international internet-based survey of 21,746 women. BMC Womens Health. 2012;12:6.CrossRef
21.
Zurück zum Zitat Wallac EE, Vlahos NF. Uterine myomas: an overview of development, clinical features and management. Obstet Gynecol. 2004;104:393–406.CrossRef Wallac EE, Vlahos NF. Uterine myomas: an overview of development, clinical features and management. Obstet Gynecol. 2004;104:393–406.CrossRef
22.
Zurück zum Zitat Donnez J, Dolmans MM. Uterine fibroid management: from the present to the future. Hum Reprod Update. 2016;22:665–86.CrossRef Donnez J, Dolmans MM. Uterine fibroid management: from the present to the future. Hum Reprod Update. 2016;22:665–86.CrossRef
23.
Zurück zum Zitat Pavone D, Clemenza S, Sorbi F, Fambrini M, Petraglia F. Epidemiology and Risk Factors of Uterine Fibroids. Best Pract Res Clin Obstet Gynaecol. 2018;46:3–11.CrossRef Pavone D, Clemenza S, Sorbi F, Fambrini M, Petraglia F. Epidemiology and Risk Factors of Uterine Fibroids. Best Pract Res Clin Obstet Gynaecol. 2018;46:3–11.CrossRef
24.
Zurück zum Zitat Sabry M, Halder SK, Ait Allah AS, Roshdy E, Rajaratnam V, Al-Hendy A. Serum vitamin D3 level inversely correlates with uterine fibroid volume in different ethnic groups: a cross-sectional observational study. Int J Womens Health. 2013;5:93–100.PubMedPubMedCentral Sabry M, Halder SK, Ait Allah AS, Roshdy E, Rajaratnam V, Al-Hendy A. Serum vitamin D3 level inversely correlates with uterine fibroid volume in different ethnic groups: a cross-sectional observational study. Int J Womens Health. 2013;5:93–100.PubMedPubMedCentral
Metadaten
Titel
Evaluation of vitamin D receptor expression in uterine leiomyoma and nonneoplastic myometrial tissue: a cross‐sectional controlled study
verfasst von
Maria Simone Oliveira Lima
Benedito Borges da Silva
Menandro Lima de Medeiros
Alesse Ribeiro dos Santos
Emerson Davi do Nascimento Brazil
Walberto Monteiro Neiva Eulálio Filho
Jerusia Oliveira Ibiapina
Antônio Gilberto Albuquerque Brito
Pedro Vitor Lopes Costa
Publikationsdatum
01.12.2021
Verlag
BioMed Central
Erschienen in
Reproductive Biology and Endocrinology / Ausgabe 1/2021
Elektronische ISSN: 1477-7827
DOI
https://doi.org/10.1186/s12958-021-00752-x

Weitere Artikel der Ausgabe 1/2021

Reproductive Biology and Endocrinology 1/2021 Zur Ausgabe

Hirsutismus bei PCOS: Laser- und Lichttherapien helfen

26.04.2024 Hirsutismus Nachrichten

Laser- und Lichtbehandlungen können bei Frauen mit polyzystischem Ovarialsyndrom (PCOS) den übermäßigen Haarwuchs verringern und das Wohlbefinden verbessern – bei alleiniger Anwendung oder in Kombination mit Medikamenten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Bislang gibt es kein Medikament zur Prävention von Wochenbettdepressionen. Das Injektionsanästhetikum Esketamin könnte womöglich diese Lücke füllen.

Bei RSV-Impfung vor 60. Lebensjahr über Off-Label-Gebrauch aufklären!

22.04.2024 DGIM 2024 Kongressbericht

Durch die Häufung nach der COVID-19-Pandemie sind Infektionen mit dem Respiratorischen Synzytial-Virus (RSV) in den Fokus gerückt. Fachgesellschaften empfehlen eine Impfung inzwischen nicht nur für Säuglinge und Kleinkinder.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.